In vivo/in vitro evaluation of antioxidant activity of drugs for lifestyle disease.

血管紧张素II型1 （AT1）受体阻滞剂（ARBs）抑制肾素-血管紧张醛固酮系统（RAAS），已被证明对治疗高血压有效。最近，除了降低血压（BP）的能力外，arb还被报道对心血管和肾脏疾病有保护作用。抗氧化活性被认为是最重要的保护作用之一，在体外研究中提出了几种机制。然而，奥美沙坦的抗氧化作用尚未在体内研究中得到广泛的检验。因此，本研究的目的是利用氧化白蛋白（氧化应激的敏感标志物）在体内和体外评价系统中检测奥美沙坦的抗氧化活性。因此，在体外和体内研究中，奥美沙坦有效地降低了白蛋白的氧化损伤程度。奥美沙坦的抗氧化活性与其肾保护作用密切相关，而与降压作用无关。奥美沙坦的直接和间接抗氧化作用可能是由于其共同的核心结构通过调节NADPH氧化酶活性而产生的。因此，奥美沙坦在抗高血压作用的基础上，还应进一步探讨其作为抗氧化药物的潜在适应症。这些结果对于开发对心血管和肾脏疾病具有重要保护作用的新型ARB具有重要意义。

Angiotensin II type 1 (AT1) receptor blockers (ARBs) inhibit the renin-angiotensinaldosterone system (RAAS) and have been shown to be effective for treating hypertension. Recently, apart from their ability to lower blood pressure (BP), ARBs had also been reported to show protective effects in cardiovascular and renal diseases. Antioxidant activity is thought to be one of the most important protective effects and several mechanisms have been proposed in the in vitro studies. However, the antioxidant effect of olmesartan has not been extensively examined in the in vivo studies. Therefore, the aim of this study was to examine the antioxidant activity of olmesartan by utilizing oxidized albumin, a sensitive marker of oxidative stress, in the in vivo and in vitro evaluation systems. As a result, olmesartan effectively lowered the extent of oxidative damage to albumin in the in vitro and the in vivo studies. The antioxidant activity of olmesartan is greatly related to its renoprotective effects but not its antihypertensive effect. It is possible that the direct and indirect antioxidant effect of olmesartan is due to its common core structure through modulation of NADPH oxidase activity. Therefore, the potential indication of olmesartan as an antioxidant drug in addition to its antihypertensive effect should be explored. These results are important for developing a new ARB, which has a great protective effect in cardiovascular and renal diseases.